Ii is shown from statistical data reported to the Swedish Cancer Registry that in cases of prostatic carcinoma the long-term T-year survival rate is the final outcome of a complex interplay of multiple factors including diagnostic technology and techniques for staging and grading. Assessment of the value of specific therapy is not possible except in controlled clinical trials. The T-year survival rate per se does not give an accurate estimate of the effect of treatment.